Noxopharm Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NOXOF research report →
About the company
Noxopharm Limited, a pharmaceutical company, is focused on developing therapeutic solutions for a range of solid tumor cancers and septic shock, catering to both Australian and international markets. Its primary asset, Veyonda, is currently being developed as an adjuvant therapy, intended to complement chemotherapy and radiotherapy in the treatment of late-stage cancers. The company's robust pipeline includes several programs: The DARRT program, currently in Phase 1b/2a, targets metastatic castration-resistant prostate cancer and other solid tumor types.
- CEO
- Gisela Mautner
- IPO
- 2020
- HQ
- Chatswood, NSW, AU
Price Chart
- Market Cap
- $14.78M
- P/E
- -4.89
- P/S
- 16.98
- P/B
- -23.85
- EV/EBITDA
- -5.28
- Div Yield
- 0.00%
- Gross Margin
- -63.20%
- Op Margin
- -532.32%
- Net Margin
- -329.78%
- ROE
- 2509.60%
- ROIC
- -149.71%
- Revenue
- $2.40M · -60.06%
- Net Income
- $-3,578,117 · 76.24%
- EPS
- $-0.01 · 76.31%
- Op Income
- $-7,535,002
- FCF YoY
- 93.75%
- 52W High
- $0.04
- 52W Low
- $0.04
- 50D MA
- $0.04
- 200D MA
- $0.04
- Beta
- 0.14
- Avg Volume
- 1.15K
Get TickerSpark's AI analysis on NOXOF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our NOXOF coverage
Recent articles, reports, and earnings notes.
No research on NOXOF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NOXOF report →Similar companies
Peers in the same neighborhood.